PinCell

Executive Summary

PinCell is a pre-clinical stage biotech company based in Milan, Italy, dedicated to developing first-in-class therapies for rare and chronic inflammatory skin diseases with high unmet medical need. Founded in 2015 as an academic spin-off from the University of Modena and Reggio Emilia, the company focuses on targeting novel pathological pathways involving programmed cell death mechanisms to create disease-modifying treatments. As a private entity, PinCell has not disclosed total funding or valuation, and its current stage indicates it has not yet entered clinical trials. The company's core research positions it in the regenerative medicine and cell therapy space, aiming to address conditions where existing treatments are inadequate. PinCell's early-stage status and specialized niche present both risks and opportunities, with potential for significant impact if its preclinical programs successfully translate to clinical candidates.

Upcoming Catalysts (preview)

• Q4 2026IND-enabling studies completion60% success
• H1 2027Series A funding round50% success
• TBDLicensing or partnership deal35% success